Knight Therapeutics (TSE:GUD - Get Free Report) was upgraded by Raymond James to a "moderate buy" rating in a research report issued on Friday,Zacks.com reports. Raymond James also issued estimates for Knight Therapeutics' Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.
A number of other equities research analysts have also issued reports on GUD. Stifel Canada raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 12th. Stifel Nicolaus raised Knight Therapeutics from a "hold" rating to a "buy" rating and raised their price target for the stock from C$5.75 to C$6.75 in a research note on Tuesday, August 13th.
View Our Latest Report on Knight Therapeutics
Knight Therapeutics Trading Down 0.6 %
Shares of Knight Therapeutics stock traded down C$0.03 on Friday, reaching C$5.19. The company had a trading volume of 103,800 shares, compared to its average volume of 69,560. The firm has a market cap of C$525.28 million, a price-to-earnings ratio of -25.95, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The firm's 50-day moving average price is C$5.71 and its two-hundred day moving average price is C$5.73. Knight Therapeutics has a 1 year low of C$5.07 and a 1 year high of C$6.23.
Insider Buying and Selling at Knight Therapeutics
In other news, Senior Officer Amal Khouri sold 5,000 shares of the business's stock in a transaction on Monday, August 19th. The stock was sold at an average price of C$5.78, for a total value of C$28,919.00. Also, insider Sime Armoyan sold 300,000 shares of the business's stock in a transaction on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00. 45.62% of the stock is currently owned by corporate insiders.
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Further Reading
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
